ClinicalTrials.gg
CompletedNCT03030105Updated Oct 16, 2018

Study to Evaluate the Effects of BPN14770 on Scopolamine-induced Cognitive Impairment in Healthy Volunteers

A Phase 1 interventional study of BPN14770 and BPN14770 placebo in Alzheimer Disease, sponsored by Tetra Discovery Partners. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-10-16.

Sponsored by Tetra Discovery Partners (part of Shionogi) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
38
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 1,940 studies in Alzheimer Disease with a site in United States — 346 open to participants now, 445 under way, 40 of them phase 3. Alzheimer Disease · United States.

Enrollment
1,080th of 1,609
38 · median 73
Started
2017
with 68 others
Phase 1
304 of 1,940
31 open now
Registered
836th of 1,940
by date

Among the 1,940 studies in Alzheimer Disease with a site in United States, this one is the 1,080th largest by enrollment of the 1,609 interventional ones that give a count, is one of 69 that started in 2017, is one of 304 in phase 1, and was the 836th registered.

Alzheimer Disease

3,970 studies on the registry are indexed under Alzheimer Disease; 928 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

346 of the 1,940 studies in Alzheimer Disease with a site in United States are open now. Recruiting first, the newest first:

341 more — sign in →

All 346 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,940 studies in Alzheimer Disease with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 1, randomized, double-blind, placebo-controlled, 6-period crossover study to evaluate the effects of BPN14770 10 mg and 50 mg in reversing scopolamine-induced cognitive impairment in healthy volunteers. A positive control, donepezil 10 mg, will be included, and additivity of BPN14770 50 mg to donepezil 10 mg in reversing scopolamine effects will also be evaluated.

Read the detailed description

A total of 38 subjects will be enrolled into the study. The study duration will be up to 12 weeks with 6 weeks of single-dose Treatment Visits. The study will consist of a Screening Visit (up to 28 days prior to first study drug administration), six inpatient Treatment Visits (Periods 1 through 6), and a Follow-Up/Early Termination Visit (7-10 days after the last dose of study medication). An additional study visit may be necessary to complete the required cognitive test familiarization if not completed during the Screening Visit. Each Treatment Visit will occur approximately one week apart, allowing a 6 to 8 day washout period.

Subjects will be randomized to 1 of 6 treatment sequences based on a computer-generated randomization schedule. Subjects will receive all 6 treatments as specified by the treatment sequence according to a 6 × 6 Williams Latin square design. The following treatments will be administered:

A. Scopolamine placebo + BPN14770 placebo + donepezil placebo

B. Scopolamine 0.5 mg + BPN14770 placebo + donepezil placebo

C. Scopolamine 0.5 mg + BPN14770 10 mg + donepezil placebo

D. Scopolamine 0.5 mg + BPN14770 50 mg + donepezil placebo

E. Scopolamine 0.5 mg + donepezil 10 mg +BPN14770 placebo

F. Scopolamine 0.5 mg + BPN14770 50 mg + donepezil 10 mg

During each of the Treatment Visits (Periods 1 through 6), subjects will be admitted to the Clinical Research Unit (CRU) the day prior to each study drug administration (Day -1) and discharged the day after study drug administration (Day 2). On the morning of study drug administration (Day 1), subjects will be given study drug (BPN14770, donepezil, or placebo) with 240mL of room temperature water 2 hours prior to the scopolamine or scopolamine placebo sc injection. The timing for study drug administration will be referred to as t-2 (Hour -2). Breakfast should be available approximately 30 minutes following the morning drug administration. Two hours after study drug administration, the scopolamine or scopolamine placebo sc injection will be administered. The time at which the scopolamine or scopolamine placebo sc injection is administered will be referred to as t0 (Hour 0).

Cognitive testing will be performed 30 minutes prior to treatment with scopolamine injection and at hours 1, 2, 3, 4, and 6 post-scopolamine injection.

PK samples will be collected during the treatment period to confirm study drug is present.

Safety assessments throughout the study will include physical exams, ECGs, vital signs, chemistry, hematology, and urinalysis.

03

Conditions studied

  • Alzheimer Disease

Keywords

  • Cognition
  • Dementia
  • Phosphodiesterase Type 4D
  • PDE4D
  • Scopolamine
  • Donepezil
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy males or females between the ages of 18 to 55 years at Screening.
  2. between 18 kg/m2 to 33 kg/m2, inclusive, and body weight of >50 kg (110 pounds).
  3. Female subjects must be surgically sterile (bilateral tubal ligation, hysterectomy, or bilateral oophorectomy at least 6 months prior to first study drug administration), at least two years , or willing to either (1) utilize hormonal plus use one barrier method or (2) use two barrier methods of contraception from initial screening until one month after taking the final dose. Barrier methods of contraception include diaphragm, cervical cap, male condom, female condom, and spermicidal foam and sponges. An intrauterine device (IUD) is also considered a barrier method of contraception in this study; if the subject is using an IUD, she will need to use an additional barrier method of contraception. Menopausal status will be verified by testing for follicle stimulating hormone (FSH ≥25 mIU/mL) at Screening. In addition, all females must have a negative blood test for pregnancy within 28 days during the Screening period and negative urine test for pregnancy on Day-1 of each Treatment Visit regardless of .
  4. Male subjects must be willing to inform female partners of their participation in the study and must agree to use adequate contraceptive methods (vasectomy performed at least 6 months prior to first study drug administration, or use at least one barrier method of birth control).
  5. Able to understand the study procedures, voluntarily consent to participate in this study, and provide written prior to start of any study-specific procedures.
  6. Willing and able to remain in the study unit for the required periods and return for each treatment of the six treatment periods, including the outpatient visits.

Exclusion criteria

Exclusion Criteria:

  1. abnormality, in the Investigator's judgement, in Screening hematology, chemistry, or urinalysis tests, or from medical history, social history, vital sign, or physical examination
  2. Active liver disease or positive serology results for surface antigen (HbsAg), virus (HCV), or (HIV).
  3. Abnormal liver function test at the Screening Visit ( or alanine aminotransferase >2 × the [ULN]; total >1.5 × ULN; or alkaline phosphatase >2 × ULN based on appropriate age and gender normal values).
  4. Current or past history of angle closure glaucoma, or diagnosis of angle closure glaucoma.
  5. Marked hypotension (systolic blood pressure [BP] ˂90 mmHg or diastolic BP ˂50 mmHg) or hypertension (systolic BP ˃150 mmHg or diastolic BP ˃100 mmHg) based on sitting values obtained. Out-of-range results may be repeated once at Screening. This exclusion applies to the vital signs performed at Screening and on Day -1 on Treatment Period 1.
  6. Marked bradycardia (heart rate ˂45 beats per minute [bpm]) or tachycardia (heart rate ˃110 bpm) based on supine values obtained. Out-of-range results may be repeated once at Screening. This exclusion applies to the vital signs performed at Screening and on Day -1 on Treatment Period 1.
  7. Current or past history of significant (in the Investigator's judgement) cardiovascular, cerebrovascular, pulmonary, renal, or liver disease. Stable, well-controlled hypertension and hyperlipidemias are allowed.
  8. Clinically important or significant conduction abnormalities on single ECG or evidence or history of long syndrome based on supine ECG values obtained at Screening. Out-of-range results may be repeated once at Screening.
  9. Current or past history of gastric or duodenal ulcers or other diseases of the gastrointestinal tract that could interfere with absorption of study drug. Note: Subjects with a history of appendectomy or cholecystectomy may be enrolled.
  10. Active acute or chronic infectious diseases.
  11. Unable to discontinue medications including anticholinergic agents, psychotropic drugs, sedative antihistamines, or other centrally active medications [e.g., CNS- penetrant beta blockers], and moderate to strong inhibitors or inducers of , CYP2D6, or other cytochromes) 14 days prior to the first dose of study drug (Period 1, Day 1) and during the study (Follow-Up). Other prescription or non-prescription drugs such as antihypertensive or cholesterol lowering drugs are allowed, if, in the Investigator's judgement, they would not interfere with the study medication or the cognitive testing.
  12. Unable to discontinue and abstain from over-the-counter, herbal preparations, dietary supplements, nutraceuticals, vitamins and minerals at least 7 days prior to the first dose of study drug and during the study. The one exception to this rule is acetaminophen, which may be taken for minor ailments at doses up to 1000 mg per day.
  13. Any history of alcohol or other substance abuse, including marijuana, within the previous year prior to the Screening visit (per the current edition of the , 5th Edition: DSM-5), or regular (daily) consumption of alcohol exceeding two bottles of beer, or the equivalent amount of other forms of alcohol (1 serving = 12 oz beer, 5.0 oz wine, or 1.5 oz distilled spirits).
  14. Any use of alcohol, grapefruit, marijuana, or other psychotropic agent within 12 hours of admission into the CRU.
  15. Active smokers or tobacco users (e.g., chew and snuff) who are unable to discontinue tobacco use or nicotine-containing products (including e-cigarettes) at least 4 weeks prior to Screening and to refrain from using during the study.
  16. Inability or unwillingness to comply with the protocol or likely inability to complete the study.
  17. Participation in other clinical studies involving drug within the previous 30 days prior to the Screening Visit.
  18. Donation of blood within the prior 4 weeks, or blood products within the prior 2 weeks, prior to first study drug administration.
  19. Positive result for drugs of abuse, alcohol, or cotinine at Screening, or a positive drug or alcohol (breath) result upon admission to CRU.
  20. History of clinically significant drug allergy that includes symptoms such as shortness of breath, rash, or edema. This includes known to donepezil hydrochloride, scopolamine, or belladonna, alkaloids.
  21. Inability or unwillingness to perform the Cogstate cognitive function tests.
  22. A suicidal ideation intensity score of 2 or higher per screening Columbia Suicide Severity Rating Scale (C-SSRS) assessment and/or any suicidal behavior within the past 28 days.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
38 participants (actual)

Study arms

  • Placebo comparator
    A) P:P:P

    Scopolamine placebo : BPN14770 placebo : Donepezil placebo

    Drug: BPN14770 placebo · Drug: Donepezil placebo · Drug: Scopolamine placebo

  • Placebo comparator
    B) S:P:P

    Scopolamine 0.5mg : BPN14770 placebo : Donepezil placebo

    Drug: BPN14770 placebo · Drug: Donepezil placebo · Drug: Scopolamine 0.6 MG/ML

  • Experimental
    C) S:B:P

    Scopolamine 0.5mg : BPN14770 10mg : Donepezil placebo

    Drug: BPN14770 · Drug: Donepezil placebo · Drug: Scopolamine 0.6 MG/ML

  • Experimental
    D) S:B:P

    Scopolamine 0.5mg : BPN14770 50mg : Donepezil placebo

    Drug: BPN14770 · Drug: Donepezil placebo · Drug: Scopolamine 0.6 MG/ML

  • Active comparator
    E) S:P:D

    Scopolamine 0.5mg : BPN14770 placebo : Donepezil 10mg

    Drug: BPN14770 placebo · Drug: Donepezil · Drug: Scopolamine 0.6 MG/ML

  • Experimental
    F) S:B:D

    Scopolamine 0.5mg : BPN14770 50mg : Donepezil 10mg

    Drug: BPN14770 · Drug: Donepezil · Drug: Scopolamine 0.6 MG/ML

Interventions

  • investigational drug

  • DrugBPN14770 placebo

    placebo

  • comparator

    Also known as: Aricept

  • DrugDonepezil placebo

    placebo

    Also known as: Aricept placebo

  • DrugScopolamine 0.6 MG/ML

    Drug page: Scopolamine

    cognition impairment

    Also known as: Hyoscine s.c.

  • DrugScopolamine placebo

    placebo

    Also known as: Hyoscine s.c. placebo

06

What researchers measure

Primary outcomes

  1. Groton Maze Learning Test (GMLT)

    Time frame: 2 hours post-scopolamine s.c. injection

Other outcomes

  1. Detection Test (DET)

    Time frame: 30 minutes prior and at 1, 2, 3, 4, and 6 hours post-scopolamine sc injection

  2. One Card Learning Test (OCL)

    Time frame: 30 minutes prior and at 1, 2, 3, 4, and 6 hours post-scopolamine sc injection

  3. One Back Test (ONB)

    Time frame: 30 minutes prior and at 1, 2, 3, 4, and 6 hours post-scopolamine sc injection

  4. Two Back Test (TWOB)

    Time frame: 30 minutes prior and at 1, 2, 3, 4, and 6 hours post-scopolamine sc injection

  5. Physical exam, vital signs, clinical laboratory, ECG

    To evaluate the safety and tolerability of BPN14770 in healthy subjects

    Time frame: Study duration up to 12 weeks

  6. Plasma concentrations of BPN14770

    To obtain pharmacokinetic data on BPN14770

    Time frame: Plasma BPN14770 concentrations at 0, 2.5, 4.5 and 6.5 hours post-scopolamine sc injection

07

Study locations

1 site
  • ICON Early Phase Services, LLC
    Austin, Texas 78209, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2017 to primary completion in May 2017, 4 months.

Of 161 industry-sponsored phase 1 interventional studies under Alzheimer Disease, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 23. This study's 4 months is below that.

Counting every sponsor, half of 234 studies reached it within 18 months; a quarter within 7 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 17, 2017
First posted
Jan 24, 2017
StartActual
Jan 2017
Primary completionActual
May 2017
CompletionActual
Jun 2017
Last update
Oct 16, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 16, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03030105
Responsible party
Sponsor
First posted
Jan 24, 2017
Start date
Jan 2017
Primary completion
May 2017
Completion
Jun 2017
Last update
Oct 16, 2018

Study contacts

Cassandra Key, MD
principal investigator · ICON Early Phase Services, LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: BPN14770 · Scopolamine

Start the discussion